|
1
|
Morris SW, Naeve C, Mathew P, et al: ALK,
the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s
lymphoma, encodes a novel neural receptor tyrosine kinase that is
highly related to leukocyte tyrosine kinase (LTK). Oncogene.
14:2175–2188. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Iwahara T, Fujimoto J, Wen D, et al:
Molecular characterization of ALK, a receptor tyrosine kinase
expressed specifically in the nervous system. Oncogene. 14:439–449.
1997. View Article : Google Scholar
|
|
3
|
Pulford K, Lamant L, Morris SW, et al:
Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein
nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells
with the monoclonal antibody ALK1. Blood. 89:1394–1404.
1997.PubMed/NCBI
|
|
4
|
Zhang X, Zhang S, Yang X, et al: Fusion of
EML4 and ALK is associated with development of lung adenocarcinomas
lacking EGFR and KRAS mutations and is correlated with ALK
expression. Mol Cancer. 13:1882010. View Article : Google Scholar
|
|
5
|
Salido M, Pijuan L, Martinez-Aviles L, et
al: Increased ALK gene copy number and amplification are frequent
in non-small cell lung cancer. J Thorac Oncol. 6:21–27. 2011.
View Article : Google Scholar
|
|
6
|
Coffin CM, Hornick JL and Fletcher CD:
Inflammatory myofibroblastic tumor: comparison of
clinicopathologic, histologic, and immunohistochemical features
including ALK expression in atypical and aggressive cases. Am J
Surg Pathol. 31:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cessna MH, Zhou H, Sanger WG, et al:
Expression of ALK1 and p80 in inflammatory myofibroblastic tumor
and its mesenchymal mimics: a study of 135 cases. Mod Pathol.
15:931–938. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Brouwer BS, De Preter K, Kumps C, et
al: Meta-analysis of neuroblastomas reveals a skewed ALK mutation
spectrum in tumors with MYCN amplification. Clin Cancer Res.
16:4353–4362. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen Y, Takita J, Choi YL, et al:
Oncogenic mutations of ALK kinase in neuroblastoma. Nature.
455:971–974. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
George RE, Sanda T, Hanna M, et al:
Activating mutations in ALK provide a therapeutic target in
neuroblastoma. Nature. 455:975–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mossé YP, Laudenslager M, Longo L, et al:
Identification of ALK as a major familial neuroblastoma
predisposition gene. Nature. 455:930–935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Janoueix-Lerosey I, Lequin D, Brugieres L,
et al: Somatic and germline activating mutations of the ALK kinase
receptor in neuroblastoma. Nature. 455:967–970. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morris SW, Kirstein MN, Valentine MB, et
al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM,
in non-Hodgkin’s lymphoma. Science. 263:1281–1284. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshida A, Shibata T, Wakai S, et al:
Anaplastic lymphoma kinase status in rhabdomyosarcomas. Mod Pathol.
26:772–781. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van Gaal JC, Flucke UE, Roeffen MH, et al:
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma:
clinical and prognostic implications. J Clin Oncol. 30:308–315.
2012. View Article : Google Scholar
|
|
16
|
Takeuchi K, Choi YL, Togashi Y, et al:
KIF5B-ALK, a novel fusion oncokinase identified by an
immunohistochemistry-based diagnostic system for ALK-positive lung
cancer. Clin Cancer Res. 15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kasprzycka M, Marzec M, Liu X, et al:
Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein
induces the T regulatory cell phenotype by activating STAT3. Proc
Natl Acad Sci. 103:9964–9969. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiarle R, Simmons WJ, Cai H, et al: Stat3
is required for ALK-mediated lymphomagenesis and provides a
possible therapeutic target. Nat Med. 11:623–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bai RY, Ouyang T, Miething C, et al:
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic
large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt
antiapoptotic signaling pathway. Blood. 96:4319–4327.
2000.PubMed/NCBI
|
|
20
|
Zou HY, Li Q, Lee JH, et al: An orally
available small-molecule inhibitor of c-Met, PF-2341066, exhibits
cytoreductive antitumor efficacy through antiproliferative and
antiangiogenic mechanisms. Cancer Res. 67:4408–4417. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang YW, Tu PH, Lin KT, et al:
Identification of oncogenic point mutations and
hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.
Neoplasia. 13:704–715. 2011.PubMed/NCBI
|
|
22
|
Fletcher CDM, Bridge JA, Hogendoorn PCW
and Mertens F: World Health Organization Classification of Tumours
of Soft Tissue and Bone. IARC Press; Lyon: pp. 333–365. 2013
|
|
23
|
Li XQ, Hisaoka M, Shi DR, et al:
Expression of anaplastic lymphoma kinase in soft tissue tumors: an
immunohistochemical and molecular study of 249 cases. Hum Pathol.
35:711–721. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Duijkers FA, Gaal J, Meijerink JP, et al:
Anaplastic lymphoma kinase (ALK) inhibitor response in
neuroblastoma is highly correlated with ALK mutation status, ALK
mRNA and protein levels. Cell Oncol. 34:409–417. 2011. View Article : Google Scholar
|
|
25
|
Katayama R, Shaw AT, Khan TM, et al:
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung
cancers. Sci Transl Med. 4:120ra172012.PubMed/NCBI
|
|
26
|
Palmer RH, Vernersson E, Grabbe C and
Hallberg B: Anaplastic lymphoma kinase: signalling in development
and disease. Biochem J. 420:345–361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Camidge DR, Bang YJ, Kwak EL, et al:
Activity and safety of crizotinib in patients with ALK-positive
non-small-cell lung cancer: updated results from a phase 1 study.
Lancet Oncol. 13:1011–1019. 2012. View Article : Google Scholar : PubMed/NCBI
|
